Impact of COVID-19 infection on the cardiovascular system: An evidence-based analysis of risk factors and outcomes.

Autor:	Kaye AD; Department of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. Electronic address: akaye@lsuhsc.edu., Spence AL; Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, CO, 80221, USA. Electronic address: aspence002@regis.edu., Mayerle M; Regis University School of Pharmacy, Denver, CO, 80221, USA. Electronic address: mmayerle@regis.edu., Sardana N; Rutgers Robert Wood Johnson Medical School, 675 Hoes Ln W, Piscataway, NJ, 08854, USA. Electronic address: nitish.sardana@rutgers.edu., Clay CM; LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. Electronic address: CClay2@lsuhsc.edu., Eng MR; Department of Anesthesiology, LSU Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA, 70112, USA. Electronic address: meng@lsuhsc.edu., Luedi MM; Bern University Hospital Inselspital, University of Bern, Bern, Switzerland. Electronic address: Markus.luedi2@insel.ch., Carroll Turpin MA; Department of Biomedical Sciences, College of Medicine, University of Houston, Health 2 Building, Room, 8037, USA. Electronic address: macarrol@central.uh.edu., Urman RD; Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115, USA. Electronic address: rurman@bwh.harvard.edu., Cornett EM; Department of Anesthesiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. Electronic address: ecorne@lsuhsc.edu.
Jazyk:	angličtina
Zdroj:	Best practice & research. Clinical anaesthesiology [Best Pract Res Clin Anaesthesiol] 2021 Oct; Vol. 35 (3), pp. 437-448. Date of Electronic Publication: 2021 Mar 01.
DOI:	10.1016/j.bpa.2021.02.003
Abstrakt:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, emerged in late 2019 in Wuhan, China. The World Health Organization declared the virus a pandemic on March 11, 2020. Disease progression from COVID-19 infection has shown significant symptom manifestations within organ systems beyond the respiratory system. The literature has shown increasing evidence of cardiovascular involvement during disease course and an associated increase in mortality among infected patients. Although the understanding of this novel virus is continually evolving, it is currently proposed that the mechanism by which the SARS-CoV-2 virus contributes to cardiovascular manifestations involves the ACE2 transmembrane protein. The protein ACE2 is highly expressed in blood vessel pericytes, and infection can result in microvascular dysfunction and subsequent acute coronary syndromes. Complications involving the cardiovascular system include myocardial infarction, arrhythmias, shock, and heart failure. In this evidence-based review, we discuss risk factors of cardiovascular involvement in COVID-19 infection, pathophysiology of COVID-19-related cardiovascular infection, and injury, COVID-19 effects on the cardiovascular system and corresponding treatments, and hematologic effects of COVID-19 and COVID-19 in heart transplant patients. Clinicians managing COVID-19 patients should appreciate the potential cardiovascular effects related to the disease process. Competing Interests: Declaration of competing interest Richard Urman reports unrelated research funding from AcelRx and fees from Medtronic, Merck, Pfizer, Heron, and Takeda. Alan Kaye reports fees from Merck. Other authors report no conflicts of interest. (Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu